Peg-intron and Warfarin sodium drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Peg-intron (peginterferon alfa-2b) and Warfarin sodium (warfarin sodium). Common drug interactions include hunger among females and loss of consciousness among males.

The phase IV clinical study analyzes what interactions people have when they take Peg-intron and Warfarin sodium. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Peg-intron?

Peg-intron has active ingredients of peginterferon alfa-2b. eHealthMe is studying from 11,142 Peg-intron users. Check the latest studies of Peg-intron.

What is Warfarin sodium?

Warfarin sodium has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 71,174 Warfarin sodium users. Check the latest studies of Warfarin sodium.

On Jul, 06, 2026

22 people who take Peg-intron and Warfarin sodium together, and have interactions are studied.

Peg-intron and Warfarin sodium drug interactions.

What are the common drug interactions of Peg-Intron and Warfarin Sodium, by gender? *:

female:

Hunger
Hyperhidrosis (abnormally increased sweating)
Hyperkalaemia (damage to or disease of the kidney)
Infection
Interstitial lung disease
Loss of consciousness
Markedly reduced food intake
Myalgia (muscle pain)
Oedema lower limb (fluid collection in tissue of lower leg)
Oral intake reduced

male:

Loss of consciousness
Coronary artery thrombosis (clot formation in coronary artery)
Blood pressure decreased
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Haemorrhage subcutaneous (bleeding from skin)
Tibia fracture (fracture of lower leg bone)
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
Anxiety
Arrhythmia (irregular heartbeat)
Arterial haemorrhage

What are the common drug interactions of Peg-Intron and Warfarin Sodium, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Anaemia (lack of blood)
Chest pain
Dizziness
Drug effect decreased
Electrocardiogram qt prolonged
Gallbladder enlargement
Hepatic enzyme increased
Hyperhidrosis (abnormally increased sweating)

50-59:

Speech disorder
Vasculitis (inflammation of a blood vessel or blood vessels)
Vertebral injury (spinal cord injury)
Weight decreased
Loss of consciousness
Coronary artery thrombosis (clot formation in coronary artery)
Dyspnoea (difficult or laboured respiration)
Fall
Head injury
Hyperthermia (body temperature greatly above normal)

60+:

Balance disorder
Blood triglycerides increased
Muscle atrophy (a decrease in the mass of the muscle)
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Nausea (feeling of having an urge to vomit)
Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery)
Photophobia (extreme sensitivity to light)
Retching (strong involuntary effort to vomit)
Tearfulness (excess tearing)
Vertigo

What are the existing conditions these people have? *

Hepatitis C: 17 people, 77.27%

* Approximation only. Some reports may have incomplete information.

Do you take Peg-intron and Warfarin sodium?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously